Lenvatinib, a multi-target tyrosine kinase inhibitor (TKI), is an emerging first-line therapy for
hepatocellular carcinoma (HCC). Its application has changed the status of sorafenib as the …

Hepatocellular carcinoma (HCC) is a common malignancy and one of the leading causes of
cancer-related death. The biological process of HCC is complex, with multiple factors …

Lenvatinib, which is an oral multikinase inhibitor, showed non-inferiority to the sorafenib in
terms of overall survival (OS) and a higher objective response rate (ORR) and better …

Objective: There is limited information regarding the benefits of Lenvatinib-transcatheter
arterial chemoembolization (LEN-TACE) sequential therapy for unresectable hepatocellular …

Simple Summary The evaluation of tumor response to anti-cancer therapy is critical in
oncology for the prompt determination of subsequent treatment and follow-up strategies …

Purpose: We aimed to construct machine learning (ML) radiomics models to predict
response to lenvatinib monotherapy for unresectable hepatocellular carcinoma (HCC) …

BACKGROUND Hepatocellular carcinoma (HCC) accompanied by portal vein tumour
thrombus (PVTT) presents an aggressive disease course, worsening liver function reserve …

Large tumor size and arterioportal shunt are poor prognostic factors for hepatocellular
carcinoma. Lenvatinib is a novel and potent multi-tyrosine kinase inhibitor developed in …

Aim We aimed to investigate the radiological antitumor response at 2 weeks after starting
lenvatinib for patients with advanced hepatocellular carcinoma in real‐world practice …

Introduction: Atezolizumab and bevacizumab (AB) therapy was the first-line treatment for
unresectable hepatocellular carcinoma (u-HCC). However, the predictive marker of …